New analysis finds hiring more specialists alone won't fix long wait times, and may make them worse
Peer-Reviewed Publication
Updates every hour. Last Updated: 27-Oct-2026 19:16 ET (27-Oct-2026 23:16 GMT/UTC)
Following the publication of its latest study in Nature Biotechnology, Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., took the stage at Sorbonne University during the Nature AI Conference on Redefining Healthcare in the Age of AI to deliver a detailed presentation of the breakthrough findings.
Addressing an audience of global research leaders, clinical investigators, and biopharma innovators, Zhavoronkov detailed how the company’s AI-driven novel drug candidate, rentosertib (ISM001-055), achieved a unanimous reversal of biological age across six independent proteomic aging clocks in a Phase IIa clinical trial.
Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient’s own immune cells to eliminate the earliest cellular drivers of age-related disease. This initiative expands the company’s dual-purpose, aging-oriented discovery strategy from small molecules into RNA-encoded, in vivo cell engineering.
Non-fatal overdoses happen far more often than fatal overdoses, yet little is known about where they occur. A study of 1,661 non-fatal overdoses in Palm Beach County found that nearly half of mapped overdose hotspots significantly overlapped with gas stations, while others followed major transportation corridors. Nearly 40% of overdoses occurred outdoors, with outdoor overdoses strongly associated with housing instability, lack of insurance and younger age. People experiencing housing instability had five times the odds of overdosing near a gas station, offering new opportunities for targeted, place-based prevention.